PUBLICATION
Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis
- Authors
- Jiang, X., Huang, Y., Wang, X., Liang, Q., Li, Y., Li, F., Fu, X., Huang, C., Liu, H.
- ID
- ZDB-PUB-170521-6
- Date
- 2017
- Source
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 91: 1065-1074 (Journal)
- Registered Authors
- Keywords
- Angiogenesis, Dianhydrogalactitol, Invasion, Migration, Multitarget agent
- MeSH Terms
-
- Humans
- Proto-Oncogene Proteins/metabolism
- Cell Line
- Vascular Endothelial Growth Factor A/metabolism
- Cell Line, Tumor
- Antineoplastic Agents/pharmacology*
- Neoplasm Invasiveness/pathology*
- Matrix Metalloproteinase 2/metabolism
- Human Umbilical Vein Endothelial Cells/drug effects
- Human Umbilical Vein Endothelial Cells/metabolism
- Neovascularization, Pathologic/drug therapy*
- Neovascularization, Pathologic/metabolism
- Zebrafish
- Animals
- Dianhydrogalactitol/pharmacology*
- Glioblastoma/drug therapy*
- Glioblastoma/metabolism
- Angiogenesis Inhibitors/pharmacology*
- Cell Proliferation/drug effects
- Vascular Endothelial Growth Factor Receptor-2/metabolism
- Cell Movement/drug effects*
- Signal Transduction/drug effects
- PubMed
- 28525947 Full text @ Biomed. Pharmacother.
- CTD
- 28525947
Citation
Jiang, X., Huang, Y., Wang, X., Liang, Q., Li, Y., Li, F., Fu, X., Huang, C., Liu, H. (2017) Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 91:1065-1074.
Abstract
The complexity of cancer has led to single-target agents exhibiting lower-than-desired clinical efficacy. Drugs with multiple targets provide a feasible option for the treatment of complex tumors. Multitarget anti-angiogenesis agents are among the new generation of anticancer drugs and have shown favorable clinical efficacy. Dianhydrogalactitol (DAG) is a chemotherapeutic agent for chronic myeloid leukemia and lung cancer. Recently, it has been tested in phase II trials of glioblastoma treatment; however, mechanisms of DAG in glioblastoma have not been elucidated. Here we show that DAG could inhibit the migration and invasion of U251 cell line by inhibiting matrix metalloproteinase-2 (MMP2) expression. Furthermore, DAG could also inhibit tumor angiogenesis in vitro as well as in the zebrafish model. Mechanistic studies reveal that DAG inhibited both VEGFR2 and FGFR1 pathways. Our results suggest that DAG may be a potential multitarget agent that can inhibit tumor migration, invasion, and angiogenesis, and the anti-angiogenic effects may be involved in dual-suppression VEGF/VEGFR2 and FGF2/FGFR1 signal pathways.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping